| Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update CL Loprinzi, C Lacchetti, J Bleeker, G Cavaletti, C Chauhan, DL Hertz, ... Journal of Clinical Oncology 38 (28), 3325-3348, 2020 | 788 | 2020 |
| Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and … KE Caudle, K Sangkuhl, M Whirl‐Carrillo, JJ Swen, CE Haidar, TE Klein, ... Clinical and translational science 13 (1), 116-124, 2020 | 494 | 2020 |
| Vincristine-induced peripheral neuropathy in pediatric cancer patients E Mora, EML Smith, C Donohoe, DL Hertz American journal of cancer research 6 (11), 2416, 2016 | 207 | 2016 |
| CYP2C8* 3 increases risk of neuropathy in breast cancer patients treated with paclitaxel DL Hertz, S Roy, AA Motsinger-Reif, A Drobish, LS Clark, HL McLeod, ... Annals of oncology 24 (6), 1472-1478, 2013 | 125 | 2013 |
| CYP2C8* 3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel DL Hertz, AA Motsinger-Reif, A Drobish, SJ Winham, HL McLeod, ... Breast cancer research and treatment 134, 401-410, 2012 | 119 | 2012 |
| Tamoxifen and CYP2D6: a contradiction of data DL Hertz, HL McLeod, WJ Irvin Jr The oncologist 17 (5), 620-630, 2012 | 91 | 2012 |
| Clinical and genome-wide analysis of cisplatin-induced peripheral neuropathy in survivors of adult-onset cancer ME Dolan, O El Charif, HE Wheeler, ER Gamazon, ... Clinical Cancer Research 23 (19), 5757-5768, 2017 | 78 | 2017 |
| Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview A Chan, DL Hertz, M Morales, EJ Adams, S Gordon, CJ Tan, NP Staff, ... Supportive care in cancer 27, 3729-3737, 2019 | 77 | 2019 |
| Evidence for Association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with Chronic Cardiotoxicity in a Cohort of Breast Cancer … DL Hertz, MV Caram, KM Kidwell, JN Thibert, C Gersch, NJ Seewald, ... Pharmacogenomics 17 (3), 231-240, 2016 | 77 | 2016 |
| Pharmacogenetics of cancer drugs DL Hertz, J Rae Annual Review of Medicine 66 (2015), 65-81, 2015 | 69 | 2015 |
| Use of pharmacogenetics for predicting cancer prognosis and treatment exposure, response and toxicity DL Hertz, HL McLeod Journal of human genetics 58 (6), 346-352, 2013 | 65 | 2013 |
| Tamoxifen dose escalation in patients with diminished CYP2D6 activity normalizes endoxifen concentrations without increasing toxicity DL Hertz, A Deal, JG Ibrahim, CM Walko, KE Weck, S Anderson, ... The oncologist 21 (7), 795-803, 2016 | 64 | 2016 |
| Paclitaxel plasma concentration after the first infusion predicts treatment-limiting peripheral neuropathy DL Hertz, KM Kidwell, K Vangipuram, F Li, MP Pai, M Burness, JJ Griggs, ... Clinical Cancer Research 24 (15), 3602-3610, 2018 | 59 | 2018 |
| Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy DL Hertz, K Owzar, S Lessans, C Wing, C Jiang, WK Kelly, J Patel, ... Clinical Cancer Research 22 (19), 4890-4900, 2016 | 58 | 2016 |
| In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles DL Hertz, AC Snavely, HL McLeod, CM Walko, JG Ibrahim, S Anderson, ... British journal of clinical pharmacology 80 (5), 1122-1130, 2015 | 53 | 2015 |
| Genetic heterogeneity beyond CYP2C8* 3 does not explain differential sensitivity to paclitaxel-induced neuropathy DL Hertz, S Roy, J Jack, AA Motsinger-Reif, A Drobish, LS Clark, ... Breast cancer research and treatment 145, 245-254, 2014 | 53 | 2014 |
| Comparison of nine tools for screening drug-drug interactions of oral oncolytics LA Marcath, J Xi, EK Hoylman, KM Kidwell, SL Kraft, DL Hertz Journal of Oncology Practice 14 (6), e368-e374, 2018 | 51 | 2018 |
| Reporting of paclitaxel-induced peripheral neuropathy symptoms to clinicians among women with breast cancer: a qualitative study TM Salgado, CS Quinn, EK Krumbach, I Wenceslao, M Gonzalez, ... Supportive Care in Cancer 28, 4163-4172, 2020 | 48 | 2020 |
| Prevalence of drug-drug interactions in oncology patients enrolled on National Clinical Trials Network oncology clinical trials LA Marcath, TD Coe, EK Hoylman, BG Redman, DL Hertz BMC cancer 18, 1-8, 2018 | 47 | 2018 |
| Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy SD Krens, HL McLeod, DL Hertz Pharmacogenomics 14 (5), 555-574, 2013 | 45 | 2013 |
Howard McLeodUtah Tech Universityכתובת אימייל מאומתת בדומיין utahtech.edu